Akums Drugs & Pharmaceuticals Overview
Get informed when a big investor buys or sells
+ Follow10.39%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Akums Drugs & Pharmaceuticals's return on equity stands at 10.39%. That is below the sector sector average of 11.67%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Akums Drugs & Pharmaceuticals sits lower the its sector benchmark (11.67%) with a ROE of 10.39%. That is roughly 11.0% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
A ROE of 10.39% for Akums Drugs & Pharmaceuticals means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.
The history chart shows how Akums Drugs & Pharmaceuticals's ROE evolved across reporting periods, while the comparison chart places AKUMS.NS next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
